| Class: | Progestin
|
LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer, but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.